New Hope for Cancer. / Michael D. Lemonick and Alice Park.
by Lemonick, Michael D; SIRS Publishing, Inc.
Material type:
BookSeries: SIRS Enduring Issues 2002Article 8Health. Publisher: Los Angeles Times Syndicate, 2001ISSN: 1522-323X;.Subject(s): Cancer -- Chemotherapy | Cancer -- Research | Drugs -- Research | Gleevec | Monoclonal antibodies | Neovascularization inhibitorsDDC classification: 050 Summary: "Gleevec is effective enough that the U.S. Food and Drug Administration approved it in record time two weeks ago--even as researchers announced that it also works against a rare form of stomach cancer. The drug doesn't help everyone, and it can have side effects....Despite all these caveats, Gleevec is still a breakthrough--not only for what it does but, more important, for the revolutionary strategy it represents." (TIME) This article discusses the success of the drug Gleevec and examines its future applications. In addition, it explains the course of cancer and reviews other available cancer medications.
| Item type | Current location | Call number | Status | Date due |
|---|---|---|---|---|
Books
|
High School - old - to delete | SIRS HEA2 8 (Browse shelf) | Available |
Articles Contained in SIRS Enduring Issues 2002.
Originally Published: New Hope for Cancer, May 28, 2001; pp. 62-69.
"Gleevec is effective enough that the U.S. Food and Drug Administration approved it in record time two weeks ago--even as researchers announced that it also works against a rare form of stomach cancer. The drug doesn't help everyone, and it can have side effects....Despite all these caveats, Gleevec is still a breakthrough--not only for what it does but, more important, for the revolutionary strategy it represents." (TIME) This article discusses the success of the drug Gleevec and examines its future applications. In addition, it explains the course of cancer and reviews other available cancer medications.
Records created from non-MARC resource.
There are no comments for this item.